Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 20-26

  Schiff, Gilbert M ^a,c   Sherwood, James R ^a,b  

^a Gamble Program for Clinical Studies   (United States)

^b Pharmaceutical Product Development   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLECONARIL;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NAUSEA; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS SHEDDING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCUS; NOSE; OXADIAZOLES; RESPIRATORY TRACT INFECTIONS; VIRUS SHEDDING;

EID: 0033955181     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315176     Document Type: Article

References (26)

1. 1. National Ambulatory Medical Care Survey. Atlanta, GA: Centers for Disease Control and Prevention, 1996.
2. 2. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:25-44.
3. 3. Berman S. Epidemiology of acute respiratory infections in children of developing countries. Rev Infect Dis 1991; 13:S454-62.
4. nd ed.). New York: Raven Press, 1991:409-50.
5. 5. Murphy F, Fauquet C, Bishop D, et al. Picornaviridae. In: Virus taxonomy: sixth report of the international committee on taxonomy of viruses. New York: Springer-Verlag, 1995:329.
6. 6. Monto AS. Studies of the community and family: acute respiratory illness and infection. Epidemiol Rev 1994; 16:351-73.
7. 7. Modlin JF. Poliomyelitis and poliovirus immunization. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: American Society of Microbiology, 1995:195.
8. 8. Wright PF, Kim-Farley RJ, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 1991; 325: 1774-9.
9. 9. Chonmaitree T, Mann L. Respiratory infections. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: American Society of Microbiology, 1995:255.
10. 10. McKinlay MA, Pevear DC, Rossmann MG. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol 1992;46:635-54.
11. 11. Fromtling RA, Castaner J. VP-63843. Drugs Future 1997;22:40-4.
12. 12. Pevear DC, Seipel ME, Pallansch M, McKinlay MA. In vitro activity of VP 63843 against field isolates of non-polio enteroviruses [abstract H99]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
13. 13. Rotbart HA, Jones A, Novelli V, Blanche S, Webster ADB. Pleconaril treatment of chronic picornaviral central nervous system infections in children with agammaglobulinemia [abstract H126]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society of Microbiology, 1997.
14. 14. Weiner LB, Rotbart HA, Gilbert DL, et al. Treatment of enterovirus meningitis with pleconaril (VP 63843), an antipicornaviral agent [abstract LB27]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society of Microbiology, 1997.
15. 15. Couch RB. Production of illness with a small-particle aerosol of Coxsackie A21. J Clin Invest 1966;44:535-42.
16. 16. Couch RB. Factors influencing responses of volunteers to inoculation with Coxsackie virus A type 21. Am Rev Respir Dis 1969; 99:24-30.
17. 17. Knight V. The use of volunteers in medical virology. In: Barger E, Melnick JL, eds. Progress in medical virology. Basel: S. Karger; 1964:1-26.
18. 18. Reed LF, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-7.
19. 19. Buckland FE, Bynoe ML, Tyrrell DA. Experiments on the spread of colds. II. Studies in volunteers with coxsackievirus A21. J Hyg (Lond) 1965;63: 327-43.
20. 20. Magee WE, Miller OV. Individual variability in antibody response of human volunteers to infection of the upper respiratory tract by Coxsackie A21 virus. J Infect Dis 1970; 122:127-138.
21. 21. Hyypiä T, Hovi T, Knowles NJ, Stanway G. Classification of enteroviruses based on molecular and biological properties. J Gen Virol 1997;78:1-11.
22. 22. Pulli T, Koskimies P, Hyypiä T. Molecular comparison of Coxsackie A virus serotypes. Virology 1995;212:30-38.
23. 23. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989;56:849-53.
24. 24. Gwaltney JM Jr. Rhinovirus infection of the normal human airway. Am J Respir Crit Care Med 1995; 152:S36-9.
25. 25. Kearns GL, Abdel-Rahman SM, James LP, et al. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob Ag Chemother 1999;43:634-8.
26. 26. Frank RA, Lasher KP. A phase I, oral, ascending, multiple-dose, double-blind, randomized, placebo-controlled tolerance and pharmacokinetic study of WIN 63843. Sanofi Winthrop Clinical Study Report 2046. ViroPharma Incorporated Study Report VP 060.